The company is trading up by 40.87% at $105.71 making it one of today’s top gainers. More than 6,434,291 shares have changed hands.
Recent news headlines for Alnylam Pharmaceuticals, Inc..
The stock last traded at $105.71 which is significantly above the 50 day moving average of $81.14 and well above the 200 day moving average of $69.12. The 50 day moving average was up $24.57 or +30.28% whereas the 200 day average was up by +52.95%.
Short traders are feeling a little more bullish on shares of Alnylam Pharmaceuticals, Inc. of late if you take into consideration the fall in short interest. The company saw a fall in short interest of -3.68% as of the latest report on August 31, 2017. Short shares decreased from 8,548,456 to 8,234,228 over that period. Days to cover increased from 12.0 to 13.0 and the short interest percentage is 0.09% as of August 31.
The following firms have recently changed their position in ALNY. As of the end of the quarter Janus Capital Management LLC had acquired 136,469 shares growing its stake by 26.6%. The value of the investment in (ALNY) went from $19,207,000 to $33,280,000 increasing 73.3% since the last quarter. Bellevue Group Ag reduced its ownership by shedding 16,871 shares a decrease of 11.9% from 03/31/2017 to 06/30/2017. Bellevue Group Ag claims 125,029 shares worth $9,972,000. The value of the position overall is up by 37.1%.
As of quarter end Rhenman & Partners Asset Management Ab had sold a total of 49,810 shares trimming its holdings by 38.3%. The value of the investment in Alnylam Pharmaceuticals, Inc. decreased from $6,663,000 to $6,396,000 a change of $267,000 quarter to quarter. Squarepoint Ops LLC augmented its stake by buying 15,730 shares an increase of 145.6%. Squarepoint Ops LLC controls 26,530 shares valued at $2,116,000. The total value of its holdings increased 281.9%.
On September 15 analysts at Nomura initiated coverage on the stock setting a rating of “Reduce”. On September 7, 2017 Barclays initiated coverage on ALNY giving it an initial rating of “Overweight” and price target of $105.00.
August 10 investment analysts at Morgan Stanley left the company rating at “Equal-Weight” but moved up the price target from $46.00 to $50.00. On August 10 Barclays kept the stock rating at “Equal-Weight” but raised the price expectation to $70.00 from $50.00.
Equity analyst Bernstein released its first research report on the stock by announcing an initial rating of “Outperform”.
As of the latest earnings report the EPS was $-5.12 and is expected to be $-5.19 for the current year with 91,733,000 shares outstanding. Next quarter’s EPS is forecasted to be $-1.35 and the next full year EPS is anticipated to be $-5.29.
Alnylam Pharmaceuticals, Inc., launched on May 8, 2003, is a biopharmaceutical company. The Company is involved in the discovery, development and commercialization of ribonucleic acid (RNA) interference (RNAi) therapeutics. The Company is focused on the use of its N-acetylgalactosamine (GalNAc)-conjugate platform for delivery of small interfering RNAs (siRNAs). Its pipeline of investigational RNAi therapeutics focuses on three Strategic Therapeutic Areas (STArs): Genetic Medicines, with multiple product candidates for the treatment of rare diseases; Cardio-Metabolic Diseases, with product candidates directed toward genetically validated, liver-expressed disease targets for unmet needs in cardiovascular and metabolic diseases, and Hepatic Infectious Diseases, with product candidates designed to address the global health challenges of hepatic infectious diseases, beginning with hepatitis B and hepatitis D viral infections. Its lead product, Patisiran, is formulated utilizing lipid nanoparticles (LNPs)..